Known targets — ChEMBL curated mechanism
ADRA1AADRA1BADRA1DADRB1ADRB2ADRB3CYP11B1DPP4FGFR1FGFR2FGFR3FGFR4HRH1JAK1JAK2JAK3KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITNAOPRD1OPRK1OPRM1PPDGFRBPIK3CDSCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASMOTYK2polrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Buciclovir. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPRT1 | P00492 | 10/20 | 0.67 |
| ▸ | PNP | P00491 | 6/20 | 0.62 |
| ▸ | TK1 | P04183 | 1/20 | 0.62 |
| ▸ | POLB | P06746 | 1/20 | 0.60 |
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.58 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.58 |
| ▸ | BLM | P54132 | 1/20 | 0.58 |
| ▸ | VCP | P55072 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.58 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Buciclovir SCHEMBL10918840 | 0.95 | TK1 (0.67) | HPRT1PNPTK1POLBMEN1 | |
| Buciclovir SCHEMBL349779 | 0.95 | TK1 (0.67) | HPRT1PNPTK1POLBMEN1 | |
| Buciclovir SCHEMBL571079 | 0.95 | TK1 (0.67) | HPRT1PNPTK1POLBMEN1 | |
| Penciclovir SCHEMBL454090 | 0.91 | HPRT1 (0.66) | HPRT1PNPTK1MEN1ALDH1A1 | |
| Penciclovir SCHEMBL4240104 | 0.91 | HPRT1 (0.66) | HPRT1PNPTK1MEN1ALDH1A1 | |
| SCHEMBL9663121 | 0.88 | TK1 (0.72) | HPRT1PNPTK1MEN1ALDH1A1 | |
| Penciclovir SCHEMBL3495 | 0.86 | TK1 (0.70) | HPRT1PNPTK1MEN1ALDH1A1 | |
| Penciclovir SCHEMBL583037 | 0.84 | TK1 (0.69) | HPRT1PNPTK1MEN1ALDH1A1 | |
| Penciclovir SCHEMBL10414021 | 0.84 | TK1 (0.69) | HPRT1PNPTK1MEN1ALDH1A1 | |
| Penciclovir SCHEMBL7192792 | 0.84 | TK1 (0.69) | HPRT1PNPTK1MEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140234271-A1 | COMPOSITIONS FOR PROLIFERATION OF CELLS AND RELATED METHODS | THE HOSPITAL FOR SICK CHILDREN (CA) | 2014-08-21 | — | — | US | disclosed |
| US-8748177-B2 | Compositions for proliferation of cells and related methods | THE HOSPITAL FOR SICK CHILDREN (CA) | 2014-06-10 | — | — | US | disclosed |
| EP-2598150-A2 | COMPOSITIONS FOR PROLIFERATION OF CELLS AND RELATED METHODS | The Hospital For Sick Children (CA) | 2013-06-05 | — | — | EP | disclosed |
| WO-2012018643-A2 | COMPOSITIONS FOR PROLIFERATION OF CELLS AND RELATED METHODS | THE HOSPITAL FOR SICK CHILDREN (CA) | 2012-02-09 | — | — | WO | disclosed |
| US-20110301105-A1 | COMPOSITIONS FOR PROLIFERATION OF CELLS AND RELATED METHODS | THE HOSPITAL FOR SICK CHILDREN (CA) | 2011-12-08 | — | — | US | disclosed |
| WO-2010039679-A1 | COMPOSITIONS FOR PROLIFERATION OF CELLS AND RELATED METHODS | THE HOSPITAL FOR SICK CHILDREN (CA) | 2010-04-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140234271-A1 | COMPOSITIONS FOR PROLIFERATION OF CELLS AND RELATED METHODS | MKI67, KRT18, PROX1 | HPRT1 2747/4885PNP 3880/4885TK1 112/4885 |
| US-20110301105-A1 | COMPOSITIONS FOR PROLIFERATION OF CELLS AND RELATED METHODS | MKI67, KRT18, PROX1 | HPRT1 2747/4885PNP 3880/4885TK1 112/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.